News Releases

Use of existing, well-established hypertension drugs could improve the outcome of cancer chemotherapy by opening up collapsed blood vessels in solid tumors.

Blood-pressure drug may help improve cancer treatment

Treatment with losartan increases drug delivery in animal models by opening collapsed tumor blood vessels

01/Oct/2013

Use of existing, well-established hypertension drugs could improve the outcome of cancer chemotherapy by opening up collapsed blood vessels in solid tumors. In their report in the online journal Nature Communications, Massachusetts General Hospital (MGH) investigators describe how the angiotensin inhibitor losartan improved the delivery of chemotherapy drugs and oxygen throughout tumors by increasing blood flow in mouse models of breast and pancreatic cancer.  A clinical trial based on the findings of this study is now underway.

"Angiotensin inhibitors are safe blood pressure medications that have been used for over a decade in patients and could be repurposed for cancer treatment," explains Rakesh K. Jain, PhD, director of the Steele Laboratory for Tumor Biology at MGH and senior author of the study.  "Unlike anti-angiogenesis drugs, which improve tumor blood flow by repairing the abnormal structure of tumor blood vessels, angiotensin inhibitors open up those vessels by releasing physical forces that are applied to tumor blood vessels when the gel-like matrix surrounding them expands with tumor growth."

Focusing on how the physical and physiological properties of tumors can inhibit cancer therapies, Jain's team previously found that losartan improves the distribution within tumors of relatively large molecules called nanomedicines by inhibiting the formation of collagen, a primary constituent of the extracellular matrix.  The current study looked at whether losartan and other drugs that block the action of angiotensin – a hormone with many functions in the body – could release the elevated forces within tumors that compress and collapse internal blood vessels.  These stresses are exerted when cancer-associated fibroblasts (CAFs) – specialized cells in the tumor microenvironment – proliferate and produce increased levels of both collagen and a gel-like substance called hyaluronan.

Top image: Before treatment with the angiotensin inhibitor losartan, stresses within a tumor caused by the buildup of collagen (blue) compress blood vessels and restrict blood flow (green). Bottom image: After losartan treatment, blood vessels open up, restoring the blood flow required for effective chemotherapy. (Vikash Chauhan, PhD, Steele Lab for Tumor Biology, Massachusetts General Hospital)


The team's experiments in several mouse models showed that both collagen and hyaluronan are involved in the compression of blood vessels within tumors and that losartan inhibited production of both molecules by CAFs through reducing the activation and overall density of these cells.  Compared with drugs called ACE inhibitors, which block angiotensin signaling in a different way, losartan and drugs of its class – termed angiotensin receptor blockers – appeared better at reducing compression within tumors.  In models of breast and pancreatic cancer, treatment with losartan alone had little effect on tumor growth, but combining losartan with standard chemotherapy drugs delayed the growth of tumors and extended survival.

"Increasing tumor blood flow in the absence of anti-cancer drugs might actually accelerate tumor growth, but we believe that combining increased blood flow with chemotherapy, radiation therapy or immunotherapy will have beneficial results," explains Jain, the Cook Professor of Radiation Oncology (Tumor Biology) at Harvard Medical School.  "Based on these findings in animal models, our colleagues at the MGH Cancer Center have initiated a clinical trial to test whether losartan can improve treatment outcomes in pancreatic cancer."  Information on this trial is available at http://clinicaltrials.gov/show/NCT01821729.

Co-lead authors of the Nature Communications report are Vikash P. Chauhan, PhD, who completed this work as a doctoral student at the Harvard School of Engineering and Applied Sciences, working with Jain in the Steele Lab; and John D. Martin, a Massachusetts Institute of Technology doctoral student currently part of Jain's team.  Additional co-authors are Hao Liu, Delphine Lacorre, Saloni Jain, Sergey Kozin, Triantafyllos Stylianopoulos, Ahmed Mousa, Xiaoxing Han, Pichet Adstamongkonkul, Peigen Huang and Yves Boucher, Steele Lab; and Zoran Popović and Moungi Bawendi, Massachusetts Institute of Technology.  

The study was supported primarily by National Cancer Institute grants P01-CA080124, R01-CA126642, R01-CA085140, R01-CA115767 and R01-CA098706, and by Department of Defense Breast Cancer Research Program Innovator Award W81XWH-10-1-0016.  The MGH and Xtuit Pharmaceuticals, a company co-founded by Jain, have applied for a patent based on the work described in this paper.

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $775 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.

 

Media Contacts: Sue McGreevey, smcgreevey@partners.org, 617 724-2764

patient

U.S. News and World Report Best Hospitals 2014-2015

U.S. News & World Report ranks Mass General #1 in New England and #2 in the nation based on our quality of care, patient safety and reputation in 16 clinical specialties.

Search the Mass General news archive

Search the archive for previously published news articles, press releases and publications.

View all departments

Departments and Centers at Mass General have a reputation for excellence in patient care. View a list of all departments.